What Does Wegovy’s Launch in China Mean as Biosimilar Competition Emerges?

Novo Nordisk

Pictured: Novo Nordisk’s headquarters in Denmark/iStock, Ole Schwander

Late last month, China’s National Medical Products Administration approved Novo Nordisk’s blockbuster GLP-1 weight loss drug Wegovy (semaglutide), opening up another multimillion-dollar market for the Danish pharma. However, the approval comes at a time when…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks

Advertise With Biotech Networks